1.中华医学会糖尿病学分会,国家基层糖尿病防治管理办公室.国家基层糖尿病防治管理指南(2022)[J].中华内科杂志, 2022, 61(7):32. 2.SGLT2Inhibitor Diabetes Drugs May Cause Ketoacidosis: FDA. Medscape. May 15, 2015. 3. OgawaW, SakaguchiK. Euglycemic...
[1]Milder TY,Stocker SL,Abdel Shaheed C,et al.Combination therapy with an SGLT2 inhibitor as initial treatment for type 2 diabetes:a systematic review and meta-analysis[J].J Clin Med.2019,8(1):45.DOI:10.3390/jcm8010045. [2]Guillausseau PJ.Influence of oral antidiabetic drugs compliance ...
[2]Ma Y, et al. Efficacy and Safety of SGLT2i Versus Other Oral Antidiabetic Drugs as Dual Therapy Add-On to Metformin in Type 2 Diabetes: A Systematic Review and Meta-Analysis.937-P. Presented at ADA 2024. [3]ADA. Diabetes Care. 2024;47(Suppl. 1):S1–S321. [4]Li Y, et al...
[1]Milder TY,Stocker SL,Abdel Shaheed C,et al.Combination therapy with an SGLT2 inhibitor as initial treatment for type 2 diabetes:a systematic review and meta-analysis[J].J Clin Med.2019,8(1):45.DOI:10.3390/jcm8010045. [2]Guillausseau PJ.Influence of oral antidiabetic drugs compliance ...
However, I can provide you with some information about SGLT2i. SGLT2i is the abbreviation for sodium-glucose linked transporter 2 inhibitors. They are a class of drugs that are used to treat type 2 diabetes. SGLT2i work by blocking the reabsorption of glucose (sugar) in the kidneys. ...
(本文由北京大学第三医院药剂科翟所迪教授及其团队选题并审校,环球医学资讯编辑完成。) 参考资料: JAMA Netw Open. 2023 Sep 5;6(9):e2335797. Sodium-Glucose Cotransporter 2 Inhibitors vs Incretin-Based Drugs and Risk of Fractures for Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/37751205/...
The information presented provides a theoretical basis for the clinical prevention and treatment of diabetes and its complications and for the development of new glucose-lowering drugs.doi:10.1186/s12933-020-01071-yLihua NiCheng YuanGuopeng Chen...
[2]Guillausseau PJ.Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes.A survey in general practice[J].Diabetes Metab,2003,29(1):79-81.DOI:10.1016/s1262-3636(07)70011-3. [3]Mosenzon O,Raz I,Wiviott SD,et al.Dapagliflozin and prevention of kidney dise...
[2] Gohda T, Murakoshi M. Sodium-Glucose Cotransporter-2 Inhibitors-Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials[J]. Int J Mol Sci, 2022,23(22). ...
[1]Milder TY,Stocker SL,Abdel Shaheed C,et al.Combination therapy with an SGLT2 inhibitor as initial treatment for type 2 diabetes:a systematic review and meta-analysis[J].J Clin Med.2019,8(1):45.DOI:10.3390/jcm8010045. [2]Guillausseau PJ.Influence of oral antidiabetic drugs compliance ...